Claudin 18 (CLDN18) overexpression is a biomarker that is not currently in clinical use in Canada that predicts response to anti-CLDN18.2 therapy and occurs in 38–43% of patients with G/GEJ adenocarcinoma [18,19]. The gene discussed is CLDN18; the disease is gastroesophageal junction adenocarcinoma.